Does the legalisation of cannabis for medicinal use impact private health insurer prescription drug expenditures?
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<record>
<leader>00000cab a2200000 4500</leader>
<controlfield tag="001">MAP20240000103</controlfield>
<controlfield tag="003">MAP</controlfield>
<controlfield tag="005">20240104193916.0</controlfield>
<controlfield tag="008">240102e20240102esp|||p |0|||b|spa d</controlfield>
<datafield tag="040" ind1=" " ind2=" ">
<subfield code="a">MAP</subfield>
<subfield code="b">spa</subfield>
<subfield code="d">MAP</subfield>
</datafield>
<datafield tag="084" ind1=" " ind2=" ">
<subfield code="a">344.1</subfield>
</datafield>
<datafield tag="100" ind1="1" ind2=" ">
<subfield code="0">MAPA20240000110</subfield>
<subfield code="a">Cook, Amanda C.</subfield>
</datafield>
<datafield tag="245" ind1="1" ind2="0">
<subfield code="a">Does the legalisation of cannabis for medicinal use impact private health insurer prescription drug expenditures?</subfield>
<subfield code="c">Amanda C. Cook, E. Tice Sirmans and Brenda Wells</subfield>
</datafield>
<datafield tag="520" ind1=" " ind2=" ">
<subfield code="a">We evaluate whether health insurer aggregate prescription drug expenditures change after the legalisation of medicinal cannabis using U.S. health insurer financial filings reported to state insurance regulators and compiled by the National Association of Insurance Commissioners for private health insurers from 2010 to 2018. We analyse this question for health insurers in the individual market, which includes plans sold on the Affordable Care Act exchanges, the small group market, which consists of fully insured plans sold to employers with fewer than 50 employees, and the large group market, which consists of fully insured plans sold to employers with more than 50 employees. For all three markets, the treatment effects are not significant. Thus, we find no impact of medical cannabis legalisation on health insurer prescription drug expenditures, despite the potential disruption to the health insurance market. Had legalisation increased prescription drug expenditures, the increases in cost would have been borne by enrollees, which is troubling since healthcare costs are rising faster than inflation</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20080626310</subfield>
<subfield code="a">Seguro de asistencia sanitaria</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20080573867</subfield>
<subfield code="a">Seguro de salud</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20080559236</subfield>
<subfield code="a">Legislación</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20080563288</subfield>
<subfield code="a">Medicamentos</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20080540821</subfield>
<subfield code="a">Drogas</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20210028717</subfield>
<subfield code="a">Sistema de distribución de medicamentos</subfield>
</datafield>
<datafield tag="650" ind1=" " ind2="4">
<subfield code="0">MAPA20080579784</subfield>
<subfield code="a">Costes económicos</subfield>
</datafield>
<datafield tag="651" ind1=" " ind2="1">
<subfield code="0">MAPA20080638337</subfield>
<subfield code="a">Estados Unidos</subfield>
</datafield>
<datafield tag="700" ind1=" " ind2=" ">
<subfield code="0">MAPA20200014911</subfield>
<subfield code="a">Tice Sirmans, E.</subfield>
</datafield>
<datafield tag="700" ind1="1" ind2=" ">
<subfield code="0">MAPA20240000134</subfield>
<subfield code="a">Wells, Brenda </subfield>
</datafield>
<datafield tag="773" ind1="0" ind2=" ">
<subfield code="w">MAP20077100215</subfield>
<subfield code="g">02/01/2024 Volumen 49 Número 1 - enero 2024 , 15 p.</subfield>
<subfield code="x">1018-5895</subfield>
<subfield code="t">Geneva papers on risk and insurance : issues and practice</subfield>
<subfield code="d">Geneva : The Geneva Association, 1976-</subfield>
</datafield>
<datafield tag="856" ind1=" " ind2=" ">
<subfield code="u">https://link.springer.com/article/10.1057/s41288-022-00284-4#Sec15</subfield>
</datafield>
<datafield tag="856" ind1="0" ind2="0">
<subfield code="y">MÁS INFORMACIÓN</subfield>
<subfield code="u">mailto:centrodocumentacion@fundacionmapfre.org?subject=Consulta%20de%20una%20publicaci%C3%B3n%20&body=Necesito%20m%C3%A1s%20informaci%C3%B3n%20sobre%20este%20documento%3A%20%0A%0A%5Banote%20aqu%C3%AD%20el%20titulo%20completo%20del%20documento%20del%20que%20desea%20informaci%C3%B3n%20y%20nos%20pondremos%20en%20contacto%20con%20usted%5D%20%0A%0AGracias%20%0A</subfield>
</datafield>
</record>
</collection>